




# New England Drug Metabolism Discussion Group

---

**2021**  
**Spring Meeting**

Webinar





**Tuesday, March 23<sup>rd</sup>, 2021**

**12:00pm EST ZOOM Webinar ([webinar registration required](#))**

*This meeting is sponsored by*

**ThermoFisher**  
SCIENTIFIC

*Entitled*

**“Plasma protein-mediated uptake of drugs and its impact  
in clearance prediction”**

*Speaker*

**David Hallifax Ph.D.**

The University of Manchester

Biography: After graduating in Applied Biology (Liverpool John Moores UK), I worked in contract research (Life Science Research UK, 1984 – 1994) performing, reporting and managing ADME studies; for example, I was responsible for the ondansetron ADME study package (rat and dog) for Glaxo's submission to the Japanese regulator (JMHW) in 1992.

From 1994 to 1997, I studied for a PhD in vitro prediction of drug metabolism, with Brian Houston at the University of Manchester (UK), sponsored by Dennis Smith of Pfizer (UK); my thesis ('Hepatocellular binding of drugs and its implications in determining metabolic clearance') characterised the saturable uptake of lipophilic amine drugs into hepatocytes.

In 1998 I worked for Vanguard Medica (UK, later Vernalis) reviewing ADME studies leading to regulatory approval of frovatriptan.

In 1999, I returned to Manchester University for a postdoctoral project on drug interaction prediction, sponsored by Scott Obach of Pfizer (US); this in vitro/in vivo work demonstrated the importance of fmCYP in DDI.

Since 2000, I have been a Research Fellow in the Centre for Applied Pharmacokinetic Research (CAPKR) at Manchester University, responsible for in vitro drug disposition studies (including supervision of PhD students and post-docs) as well as managing the CAPKR LC-MS/MS facility.

I have published about 30 papers, mostly concerning clearance prediction and DDI, and have an h-index of 20. I have given external seminars (most recently Cyprotex ADME-Tox Workshop UK, 2019) and am an experienced PhD examiner and manuscript reviewer for prominent journals

*If you have additional questions contact:*  
[secretary@nedmdg.org](mailto:secretary@nedmdg.org)

**NEDMDG STEERING COMMITTEES**

**James Baker (Chair)**

Merck  
James.baker5@merck.com

**Adrian Fretland (Vice-Chair)**

AstraZeneca  
Adrian.fretland@astrazeneca.com

**Stephen Wang (Treasurer)**

Novartis  
Stephen.wang@novartis.com

**Sirimas Sudsakorn**

(Secretary/Communications)  
Sanofi  
Sirimas.sudsakorn@sanofi.com

**Upendra Argikar**

Novartis  
Upendra.argikar@novartis.com

**Bo Feng**

Vertex Pharmaceuticals  
Bo\_feng@vrtx.com

**Hanlan Liu**

Sperogenix Therapeutics  
hanlan.liu@sperogenix.com

**Xingrong Liu**

Biogen  
Xingrong.liu@biogen.com

**Tom Chan**

Boehringer-Ingelheim  
Tom.chan@boehringer-ingelheim.com

**David J. Greenblatt**

Tufts University  
DJ.greenblatt@tufts.edu

**Dean Hickman**

Independent Consultant/Eikonizo  
Therapeutics  
deanhickman360@gmail.com

**Amit Kalgutkar**

Pfizer  
Amit.kalgutkar@pfizer.com

**Franco Lombardo**

Alkermes  
Franco.lombardo@alkermes.com

**Chandra Prakash**

Agios  
Chandra.prakash@agios.com

**Haojing Rong**

Kymera Therapeutics  
Haojing@kymeratx.com

**Wen Chyi Shyu**

Takeda Pharmaceuticals  
Wenchyi.shyu@takeda.com

**David J. Waxman**

Boston University  
Djw@bu.edu

**Nancy Wong**

Sanofi  
Nancy.wong@sanofi.com

**Zhiyang Zhao**

Alliance Pharma  
Zzhao@alliancepharmaco.com

